

T2 Biosystems (TTOO : US\$15.94)

T2 Biosystems sinks 17% in 2015

T2 Biosystems Inc, NASDAQ's 27th largest healthcare-products company by market cap, has now sank US\$3.38 (or 17.5%) year to date in 2015 to close at US\$15.94. The volume YTD has been 0.9 times average trading of 73,057 shares. Compared with the NASDAQ-100 Index which has risen 3.4% YTD, this represents a relative price change of -20.9%. In 2015 the market cap has declined US\$67.7 million.

Introduction

We are currently bearish on this stock in the long-term based on fundamental metrics, but are neutral in the short-term based on technical indicators

There are some reasons why we remain neutral on the stock for the short-term:

- Its Moving Average Convergence Divergence indicators are falling, with its 12-day EMA lower than its 26-day EMA.
- The price to 200-day MAP ratio is 0.67, a bearish indicator.

Stock Summary

Sector	Healthcare-Products
Market Cap	US\$319.4 million
Shares Outstanding	20,040,604
ISIN	US89853L1044
Relative Strength (3 mo)	19

MCap: A Historical Perspective

	Share Price (USD)	Market Cap (US\$)
Last	15.9	319.4 million

Bullish Signals

- The price is at a discount of 4.3% to the 1-month volume weighted average price of US\$16.66, which may appeal as a value proposition.
- The Stochastic indicator of 14.5 has broken through the oversold line of 20.

Other Bullish Signals:

% Growth Y.O.Y, Revenue & Net Profit



Bullish Indicators and Rank in Market:

Description	Value	Rank In Market
Price Change %	6.6	In Top 4%

Bearish Signals

- Falls to Rises: In the last three months the number of falls outnumbered rises 34:27 or 1.26:1.
- In the last 20 trading sessions there has been a net decline of 20.34%; the stock has retreated thirteen times and the biggest one day decline was 6.1% on Feb 20.
- In the NASDAQ market of 2,413 stocks traded today, the stock has a 6-month relative strength of 33 which means it has underperformed 67.0% of the market.
- Also, the relative strength percentile is falling at 33 for 6 months, 19 for 3 months and 5 for 1 month.
- The Moving Average Convergence Divergence (MACD) indicator of 12-day Exponential Moving Average (EMA) of 15.64 minus the 26-day EMA of 16.73 is negative suggesting a bearish signal.
- The Price/MAP of 0.67 for TTOO is lower than the Price/MAP for the NASDAQ-100 Index of 1.0.
- The price to 200-day MAP ratio is 0.67, a bearish indicator. In the past 200 days this ratio has been under 0.67 just eight times suggesting a support level. The 200-day MAP has decreased to US\$23.63. A decrease is another bearish indicator.
- The current short volume is 1.3 times its own historical average of 0.2%. It soared 10.3% from the previous day, lifted 3.7% from a week ago, a bearish indicator.

Other Bearish Signals: Bearish Indicators and Rank in Market:

Description	Value	Rank In Market
Volatility %	6.2	In Bottom Quartile
Price/MAP200	0.67	In Bottom Quartile
Price/MAP50	0.5	In Bottom 5%

Note

Neutral Indicators and Rank in Market:

Description	Value	Rank In Market
MCap	US\$319.4 million	In 3rd Quartile
Turnover in Quarter	US\$75.1 million	In 3rd Quartile


% Growth, Y.O.Y. (Revenue & Net Profit)



Insider Trades



Turnover Rate & Turnover Period




Trailing 3 months

Turnover	US\$75.1 million
Volume	4,151,548
Volume Index (1 is avg)	0.9

MCap: A Historical Perspective

	Share Price (USD)	Market Cap (US\$)
Last	15.9	319.4 million

YTD Comparison Stock Sector Index



Activities

T2 Biosystems Inc. develops direct detection products for diagnostic applications. The Company offers diagnostic instrument for detection of infectious diseases in blood, plasma, serum, saliva, sputum and urine. T2 Biosystems operates in the United States.

Further details can be found at
www.t2biosystems.com.

Economic Sector	Healthcare
-----------------	------------

Regulatory Announcements

Conferences/Exhibitions

March 02: Events Calendar: T2 Biosystems to Present at the Cowen Healthcare Conference

[News Story] LEXINGTON, Mass., March 2, 2015 T2 Biosystems, Inc. (Nasdaq:TTOO), a company developing innovative diagnostic products to improve patient health, today announced that John McDonough, president and chief executive officer, is scheduled to present at the Cowen Healthcare Conference on Tuesday, March 3, 2015 at 10:00 a.m.

[For more details click here.](#)

Financial Results

February 18: T2 Biosystems Reports 2014 Fourth Quarter, Full Year Results

[News Story] LEXINGTON, Mass., Feb. 17, 2015 -- T2 Biosystems (Nasdaq:TTOO) today reported operating highlights and financial results for the fourth quarter and year ended December 31, 2014. Recent operational highlights included:

<http://www.nasdaq.com/press-release/t2-biosystems-reports-2014-fourth-quarter-full-year-results-20150217-01115>

Source: Nasdaq Stock Exchange

[For more details click here.](#)

Financial Results

February 18: T2 Biosystems Reports 2014 Fourth Quarter, Full Year Results

[News Story] LEXINGTON, Mass., Feb. 17, 2015 - T2 Biosystems (Nasdaq:TTOO) today reported operating highlights and financial results for the fourth quarter and year ended December 31, 2014. Recent operational highlights included:

<http://www.nasdaq.com/press-release/t2-biosystems-reports-2014-fourth-quarter-full-year-results-20150217-01115>

Source: Nasdaq Stock Exchange

[For more details click here.](#)

Conferences/Exhibitions

February 11: Events Calendar: T2 Biosystems Announces 2014 Fourth Quarter and Year-End Results Release and Conference Call Date

LEXINGTON, Mass., Feb. 10, 2015 -- T2 Biosystems, Inc. (Nasdaq:TTOO) today announced that it will release its 2014 fourth quarter and year-end financial results after the market closes on Tuesday, February 17, 2015. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m.

[For more details click here.](#)

Conferences/Exhibitions

February 05: Events Calendar: T2 Biosystems to Present at the Leerink Global Healthcare Conference

LEXINGTON, Mass., Feb. 5, 2015 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (Nasdaq:TTOO) today announced that John McDonough, president and chief executive officer, is scheduled to present at the Leerink Global Healthcare Conference on Thursday, February 12, 2015, at 8:05 a.m. ET at the Waldorf Astoria Hotel in New York City.

A live, listen-only webcast of the presentation may be accessed by visiting the Events & Presentations section of the Company's website at www.t2biosystems.com under Investors & Press.

[For more details click here.](#)

Key Developments

February 03: T2 Biosystems and Canon U.S. Life Sciences Announce Joint Collaboration to Develop Novel Test Panel to Rapidly Detect Lyme Disease

[News Story] LEXINGTON, Mass., Feb. 3, 2015 T2 Biosystems, Inc. (Nasdaq:TTOO) a company developing innovative diagnostic products to improve patient health today announced that the company has entered into a multi-year, strategic agreement with Canon U.S. Life Sciences, Inc. to jointly develop a novel diagnostic test panel to rapidly detect Lyme disease, a tick-borne bacterial infection that, if left untreated, can cause chronic joint inflammation, neurological disorders and cognitive defects.

Under the terms of the agreement, T2 Biosystems will receive an upfront payment of \$2 million from Canon U.S.

[For more details click here.](#)

January 13: T2 Biosystems: Pivotal Data for T2Candida and T2Dx Published in Clinical Infectious Diseases

[News Story] LEXINGTON, Mass., Jan. 13, 2015 T2 Biosystems (Nasdaq:TTOO), a company developing innovative diagnostic products to improve patient health, today announced that results from its pivotal trial evaluating its lead products, the T2Candida(Registered) Panel and the T2Dx(Registered) Instrument were published online in the journal Clinical Infectious Diseases (CID).

[For more details click here.](#)

8-K other news

February 19: T2 Biosystems: Results of Operations and Financial Condition

[News Story]
http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1492674_000110465915012002_0001104659-15-012002.txt

Source: 8-K United States Securities and Exchange Commission

January 21: T2 Biosystems: Financial Statements and Exhibits

[News Story]
http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1492674_000110465915003647_0001104659-15-003647.txt

Source: 8-K United States Securities and Exchange Commission

December 31: T2 Biosystems: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

[News Story]

http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1492674_000110465914089654_0001104659-14-089654.txt

Source: 8-K United States Securities and Exchange Commission

October 17: T2 Biosystems: Entry into a Material Definitive Agreement

[News Story]

http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1492674_000110465914072280_0001104659-14-072280.txt

Source: 8-K United States Securities and Exchange Commission

September 23: T2 Biosystems: Other Events

[News Story]

http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1492674_000110465914067604_0001104659-14-067604.txt

Source: 8-K United States Securities and Exchange Commission

Issued Capital

Based on 20,040,604 issued equity shares the market capitalisation is US\$319.4 million. It is NASDAQ's 26th largest Healthcare-Products company by total revenue. The top sixteen shareholders hold 29.3% of the issued capital leaving a float of 70.7%.


Source

Www.BuySellSignals.com


Top 10 Shareholders

Name of Shareholder	No. of Shares	% Held
Goldman Sachs Group Inc	3,457,240	17.25
Gilder Gagnon Howe & Co Llc	1,252,683	6.25
Wellington Management Co Llp	597,470	2.98
Essex Investment Management Co Llc	151,330	0.76
Ra Capital Management Llc	138,002	0.69
Sabby Management Llc	105,367	0.53
Barclays Global Investors Uk Holdings Ltd	63,616	0.32
Geode Capital Management Llc	27,025	0.13
Morgan Stanley	25,200	0.13
Spark Investment Management Llc	15,600	0.08
Total	5,833,533	29.11


Top 16 Institutional Holdings



Weekly Price Volume Dynamics (Last 12 Weeks)



Stock v Index (Trailing Year)



Price/Moving Average Price [P/MAP]



Board and Management

David Elsbree Director

David Elsbree has served as a member of our board of directors since July 2014. From 1970 until 2004, Mr. Elsbree was employed by Deloitte & Touche, most recently as a former senior partner. Mr. Elsbree served in a number of leadership roles in the firm's high technology practice, including partner-in-charge of the New England High Technology Practice. Mr. Elsbree served on the board of directors of Art Technology Group, Inc. from June 2004 until January 2011 and on the board of directors of Acme Packet, Inc. from November 2006 until March 2013. Mr. Elsbree received his B.A. from Northeastern University. Mr. Elsbree's extensive knowledge of and experience with technology companies and financial expertise contributed to our board of directors' conclusion that he should serve as a director of our company.

Financial Results (Annual)

31 December, 2014

Annual Report: T2 Biosystems (NASDAQ:TTOO) \$US36.0m loss

Highlights

Major Common Size Ratios:

- Total current assets to Total Assets down from 95.3% to 95.2%
- Cash to Total Assets down from 94.7% to 93.3%
- Fixed Assets to Total Assets steady at 3.5%

Favourable Changes:

- EPS continued to be negative like in the previous year; however, there was an improvement from \$US-19.72 in the previous year to \$US-4.15
- Current ratio up 93.9% to 14.6
- Working capital to total assets up 7.3% to 88.6%

Unfavourable Changes:

- Loss of \$US36.0m
- Total liabilities to Total assets up 22.2% to 0.3
- Operating Cash Flow is negative

Annual

Company Name : T2 Biosystems Inc (TTOO)

December 31 Description	2014 \$US ('000)	2013 \$US ('000)	Change (%)
Sales Revenue	119.0	266.0	down 55.3
Interest	721.0	403.0	up 78.9
Profit/(Loss) after Tax	(35,960.0)	(27,518.0)	deterioration 30.7
Current Liabilities	5,172.0	4,046.0	up 27.8
Operating Cash Flow	(28,184.0)	(18,053.0)	deterioration 56.1
Performance Ratios			
Return on Equity (%)	(67.8)	na	na
Return on Assets (%)	(45.4)	(86.3)	reduced 47.4
Total Liabilities to Operating Cash Flow	(0.9)	(0.5)	deterioration 93.8
Total Liabilities/Total Assets (up 22.2% from 0.27 to 0.33)	0.3	0.3	up 22.2
Current Ratio	14.6	7.5	up 93.9
Common Size Ratios by Assets			
Total current assets to Total Assets (%)	95.2	95.3	Down 0.1
Cash to Total Assets (%)	93.3	94.7	Down 1.5
Fixed Assets to Total Assets (%)	3.5	3.5	Down 0.2
Future income tax benefit to Total Assets (%)	0.4	na	na
Current Debtors to Total Assets (%)	0.3	na	na
Common Size Ratios by Sales			

Financial Results (Annual) (continued) 31 December, 2014

Sales and marketing expenses to Sales (%)	9258.8	1888.0	Up 390.4
Interest expenses to Sales (%)	605.9	151.5	Up 299.9
Profit after tax to Sales (%)	(30218.5)	(10345.1)	Down 192.1
Per Share figures			
Sales	1.4 U.S. cents	19.1 U.S. cents	down 92.8
Cash	\$US8.5	\$US21.6	down 60.7
Working Capital	\$US8.1	\$US18.9	down 57.2
Total Liabilities	\$US3.0	\$US6.2	down 51.2
Total Assets	\$US9.1	\$US22.8	down 60.1
Current Debt	1.0 U.S. cents	1.8 U.S. cents	down 44.0
EPS Final	(\$US4.2)	(\$US19.7)	reduced 79.0
Auditor	Ernst & Young LLP		

BuySellSignals Financial Research provides equity research on over 48,000 companies listed in more than 90 countries and 120 markets across the world. BuySellSignals believes that every stock has a story to tell and that this story changes every day. To capture this story, BuySellSignals offers the latest pertinent and comprehensive information so that investors can make well-informed investment decisions.

BuySellSignals publishes equity research reports on each stock, sector and index daily to capture the latest market movements and sentiments. BuySellSignals eschews "hot tip" or headline investing in favour of high-quality, ultra-current, targeted technical and fundamental information including specific bullish and bearish signals for each stock. Insights that will guide you to the investments that are hard to find in today's hyperactive mainstream markets.

For further details on definitions and quotations from investing legends, [Click here](#)

Disclaimer: While this document is based on information sources which are considered reliable, it has been prepared without consideration of your specific investment objectives, financial situation or needs, so you should carry out your own analysis or seek professional investment advice before an investment decision is made. The document contains unbiased, independent equities data from BuySellSignals (AFS Licence 222756) and News Bites Pty Ltd, who provide round the clock data on every Australian stock and sector. Neither BuySellSignals nor News Bites are brokers, and neither have an executing, corporate advisory or investment banking function. BuySellSignals and News Bites Pty Ltd, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. The data is sourced from annual reports and company releases and may not be fully up to date. It should be used as a guide only.
